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Abstract: Series of novel bis-heterocycles bearing isoxazoline and imidazole 
moieties have been synthesized via 1,3-dipolarcycloaddition reactions. 
1HNMR, 13CNMR, IR and elemental analyses characterized the newly 
synthesized compounds. All the synthesized compounds were evaluated for 
their antimicrobial activity and were compared with the standard drugs. The 
compounds demonstrated potent to weak antimicrobial activity. 
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Introduction 
Among five membered heterocycles, isoxazoline and imidazole are represents a class of 
compounds of great importance in biological chemistry. For instance, isoxazoline posses 
biological activities like1,2 (insecticidal, antibacterial, antibiotic, antitumour, antifungal). 
Isoxazoline also serves as anti-influenza virus activity3, inhibition of human leukocyte 
elastase and cathepsin G4. In fact, Valdecoxib an isoxazoline derivative is now widely used 
in the market as anti-inflammatory drug5. Imidazole derivatives are gaining synthetic interest 
in recent years due to their broad spectrum of biological activities like anti-inflammatory6, 
analgesic7, antibacterial8 and antifungal9. 2-n-Butyl-4-chloro-5-farmyl-imidazole is a key 
intermediate for the synthesis of Losartan a nonpeptide angiotensin antagonist, which is an 
orally active antihypertensive drug10. Literature survey reveals that bis-heterocycles bearing 
isoxazoline11,12 was synthesized via 1,3-dipolar cycloaddition of aldoxime to divinyl ketone / 
sulfone using chloramine-T as dehydrating agent.  
    1,3-Dipolar cycloaddition reactions are useful tools for constructing biologically potent 
five membered heterocycles2 and nitrile oxides serves as excellent 1,3-dipoles. 
Cycloaddition of nitrile oxide to olefinic compounds are of synthetic interest, since the 
product isoxazoline obtained are the  versatile  intermediate for the  synthesis of  bifuctional  
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compounds.13 Nitrile oxides can be generated by dehydrogenation of aryl aldoximes with 
mercuric acetae14, manganese dioxide15, tert-butyl hypo chlorite16, chloramine-T etc. In our 
laboratory Rai et.al17 extensively used chloramine-T for the generation of nitrile oxide and 
nitrile imine from aldoxime and aldehyde hydrazone respectively. With this background, it 
is considered worthwhile to prepare bis-heterocycles starting from 2-n-butyl-4-chloro-(N-



































































1H NMR spectra were recorded on a Bruker AM 300 MHz spectrometer using CDCl3 as 
solvent and tetramethylsilane as internal standard. 13C NMR spectra were measured on Jeol 
400 (100MHz) instrument. The chemical shifts are expressed in δ and following 
abbreviations were used: s = singlet, d = doublet, t = triplet and m = multiplet. Infrared (IR) 
spectra were measured on Shimadzu 8300 spectrometer. Elemental analyses were obtained 
on a Vaio-EL intrument. Thinlayer chromatography (TLC) was done with pre-coated silica 
gel G plates using chloroform-acetone as eluent. 
Antimicrobial activity 
All the synthesized compounds were evaluated for antimicrobial activity by the disc 
diffusion method18 and microdilution method.19 Five bacteria and five fungal species were 
used as the antimicrobial test strains namely: Bacillus substilis, Escherichia coli, 
Pseudomonas fluorescens, Xanthomonas campestris pvs, Xanthomonas oryzae, Aspergillus 
niger, Aspergillus flavus, Fusarium oxysporium, Trichoderma species, Fusarium and 
monaliforme. Streptomycin and tetracycline were used as standard drugs against bacteria and 
nystatin was used against fungi. In all the determinations tests were performed in triplicate 
and the results were taken as a mean of at least three determinations. 
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Preparation of 4’-(2-Butyl-4-chloro-5-formyl-imidazol-1-ylmethyll-4,5-dimethoxy-
benzene (2)  
A mixture of 2-Butyl-5-chloro-3H-imidazole-4-carbaldehyde 1 (1.0 g, 5.37 mmol) and anhy. 
K2CO3 (0.90 g, 6.52 mmol) in dimethylformamide (10 mL) was stirred for 15 min at rt.  
Bromomethyl-4,5-dimethoxy-benzene (1.66 g, 5.35 mmol) was then added and the mixture 
was stirred at rt for 6 hr. After completion of the reaction (TLC toluene-ethylacetate; 7:3), 
the reaction mass was diluted with 25 mL water and the product was extracted with 
dichloromethane (25 mL). The extract was washed with water (10 mL) and then dried 
(Na2SO4) the solvent was evaporated and the remaining pale yellow oil was crystallized 
from ethanol to gave 2 as a white crystalline solid to yield 1.83 g (82%), m.p 86-87 OC.  
Synthesis of 4,5-dihydro-3-(substituted-imidazole)-5-phenylisoxazole (5a)  
A mixture of substituted-imidazole aldoxime 3 (1.0 g, 2.55 mmol), 4a (0.265 g, 2.55 mmol) 
and chloramine-T trihydrate (0.72 g, 2.56 mmol) in ethanol (20 mL) was warmed on a water 
bath for 2-3 hr. the progress of the reaction was monitored by TLC. After completion of the 
reaction the solvent was evaporated in vacuum. The residual mass was extracted into ether (25 
mL), washed successively with water (2 x 20 mL), 5% NaOH (1x10 mL), brine solution (2 x 
15 mL) and dried over anhydrous sodium sulphate. Evaporation of the solvent afforded crude 
oily substance, which was purified by column chromatography using chloroform-acetone (9:1) 
as eluent to gave the product as yellow solid (0.94 g, 69% yield), m.p.124-126 OC.  
4,5-Dihydro-3-(substituted-imidazole)-5-methyl-5-phenylisoxazole (5b)  
Obtained from substituted-imidazole aldoxime 3 (1.0 g, 2.55 mmol), 4b (0.30 g, 2.55 mmol) 
and chloramine-T trihydrate (0.72 g, 2.56 mmol) as yellow solid (0.99 g, 71% yield), and 
m.p.130-132 OC.  
4,5-Dihydro-3-(substituted-imidazole)isoxazole-5-carbonitrile (5c)  
Obtained from substituted-imidazole aldoxime 3 (1.0 g, 2.55 mmol), 4c (0.135 g, 2.55 
mmol) and chloramine-T trihydrate (0.72 g, 2.56 mmol) as yellow oil (0.78 g, 62% yield).  
5-(Chloromethyl)-4,5-dihydro-3-(substituted-imidazole)isoxazole (5d)  
Obtained from substituted-imidazole aldoxime 3 (1.0 g, 2.55 mmol), 4d (0.194 g, 2.57 
mmol) and chloramine-T trihydrate (0.72 g, 2.56 mmol) as yellow solid (0.84 g, 65% yield), 
m.p.138-140 OC.  
5-(Bromomethyl)-4,5-dihydro-3-(substituted-imidazole)isoxazole (5e)  
Obtained from substituted-imidazole aldoxime 3 (1.0 g, 2.55 mmol), 4e (0.31 g, 2.56 mmol) 
and chloramine-T trihydrate (0.72 g, 2.56 mmol) as yellow solid (1.02 g, 73% yield), and 
m.p.144-146 OC.  
(4,5-Dihydro-3-(substituted-imidazole)isoxazol-5-yl))methanol (5f)  
Obtained from substituted-imidazole aldoxime 3 (1.0 g, 2.55 mmol), 4f (0.148 g, 2.55 
mmol) and chloramine-T trihydrate (0.72 g, 2.56 mmol) as yellow oil (0.78 g, 63% yield).  
4,5-Dihydro-3-(substituted-imidazole)isoxazole-5-yl acetate (5g)  
Obtained from substituted-imidazole aldoxime 3 (1.0 g, 2.55 mmol), 4g (0.22 g, 2.55 mmol) 
and chloramine-T trihydrate (0.72 g, 2.56 mmol) as yellow solid (1.0 g, 76% yield), 
m.p.148-150 OC.  
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4,5-Dihydro-3-(substituted-imidazole)isoxazole-5-yl propionate (5h) 
Obtained from substituted-imidazole aldoxime 3 (1.0 g, 2.55 mmol), 4h (0.255 g, 2.55 
mmol) and chloramine-T trihydrate (0.72 g, 2.56 mmol) as yellow solid (1.05 g, 78% yield), 
m.p.158-160 OC.  
Results and Discussion 
The general synthetic pathway discussed hereafter is depicted in Scheme. Compound 1 was 
alkylated using bromomethyl-4,5-dimethoxy benzene and potassium carbonate in DMF. 
Then farmyl function of 2 was converted into the aldoxime 3. When oxidative 
dehydrogenation of 3 by chloramine-T (CAT) afforded nitrile oxide, which was in situ 
trapped by the different olefins 4 (a-h) under refluxing condition in ethanol. Thus produced 
compound was identified by NMR spectroscopy as 4,5-dihydro-3-(substituted-imidazole)-5-
substituted-isoxazoline 5 (a-h) in good quality and yield. The starting substrate 2-n-butyl-4-
chloro-(N-substituted)–imidazole-5-carbaldehyde 1 was prepared according to literature 
procedure.20 Compound 3 was prepared by standard procedure21. 
Antimicrobial activity 
Antimicrobial activity of all the compounds was shown in Table 1 and 2. Among the series 
of synthesized compounds, 5d and 5e shown better inhibition. Remaining compounds shown 
moderate inhibition. The better inhibition shown by 5d and 5e may be due to the presence of 
chloro and bromo group in the compound. 
Table 1. Minimal inhibitory concentration in µg mL-1[X] and Inhibitory zone in (diameter) 
mm [Y] of the synthesized compounds against tested bacterial strains by micro dilution 






















5a 21 07 26 13 23 16 25 12 23 12 
5b 22 11 26 08 23 10 25 07 21 10 
5c 19 10 17 11 20 13 19 10 23 10 
5d 17 14 14 12 13 15 11 09 15 10 
5e 18 10 15 12 15 13 12 10 15 09 
5f 22 11 26 08 23 10 25 07 21 10 
5g 21 07 26 13 23 16 25 12 23 12 
5h 22 10 21 11 25 14 22 11 24 11 
Streptomycin 19 13 13 14 12 17 - - - - 
Tetracycline - - - - - - 09 12 13 12 
Streptomycin sulfate (25 µg per disc); Tetracycline (25 µg per disc) were used as positive 
reference standard antibactierial discs, Synthesized compounds (25 µg per disc). 
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Table 2. Minimal inhibitory concentration in µg mL-1[X] and Inhibitory zone in 
(diameter) mm [Y] of the synthesized compounds against tested fungal strains by micro 






















5a 18 08 18 09 14 12 15 14 14 11 
5b 19 07 18 07 18 11 17 12 15 09 
5c 16 08 16 10 13 13 14 15 11 11 
5d 14 09 13 12 10 16 11 17 10 14 
5e 15 09 15 11 11 14 13 16 10 12 
5f 18 07 18 07 18 11 17 12 15 09 
5g 17 07 16 08 15 11 16 13 13 10 
5h 20 06 17 07 16 10 18 11 14 08 
Nystatin 15 08 15 10 11 14 12 16 09 12 
Nystatin (25 µg per disc) was used as positive reference standard antifungal discs, 
Synthesized  compounds (25 µg  per disc). 
Spectral data of the compounds 
Compound 2: 1H NMR CDCl3: δ 0.94 (t, 3H, CH3), 1.32 (m, 2H, CH2), 1,64 (m, 2H, CH2), 
2.61 (t, 2H, CH2), 3.64 (s, 6H, OCH3) 4.86 (s, 2H, CH2), 6.45 (s, 1H, ArH), 6.82 (s, 1H, ArH), 
9.50 (s, 1H, CH), 13C NMR CDCl3: δ 13.9 (C), 23.2 (C), 24.5 (C), 33.1 (C), 33.9 (C), 57.5 
(2C), 116.1 (C), 117.6 (C), 118.2 (C), 134.2 (C), 136.6 (C), 140.9 (C), 147.2 (C), 148.4 (C), 
156.2 (C), 189.2 (C). IR (KBr pellets cm-1) v 3069, .2961, 1764, 1667, 1485. Anal.Calcd. For 
C17H20BrClN2O3: C, 49.12, H, 4.85, N, 6.74%. Found: C, 49.19, H, 4.87, N 6.70 %. 
Compound 5a: 1H NMR CDCl3: δ 0.97 (t, 3H, CH3), 1.35 (m, 2H, CH2), 1,64 (m, 2H, CH2), 
2.57 (t, 2H, CH2), 3.21 (dd, 1H, J=8.2, 4-H), 3.28 (dd, 2H, J=8.2, 4-H), 3.73 (s, 6H, OCH3), 
5.02 (s, 2H, CH2), 5.20 (dd, 1H, J=4.0, 5-H), 6.42 (s, 1H, ArH), 6.78 (s, 1H, ArH), 7.21 (m, 
5H, ArH), 13C NMR CDCl3: δ 14.2 (C), 23.0 (C), 25.7 (C), 33.4 (C), 34.8 (C), 41.6 (C), 56.3 
(2C), 81.1 (C), 116.3 (C), 117.7 (C), 118.5 (C), 122.2 (C), 126.2 (C), 127.2 (2C), 127.8 (C), 
128.9 (2C), 134.5 (C), 140.7 (C), 148.0 (C), 148.7 (C), 149.0 (C), 164.7 (C). Anal.Calcd. For 
C25H27BrClN3O3; C, 56.35; H, 5.11; N, 7.89; Found: C, 56.37; H, 5.13; N, 7.87 %. 
Compound (5b): 1H NMR CDCl3: δ 0.95 (t, 3H, CH3), 1.33 (m, 2H, CH2), 1.59 (s, 3H, 
CH3), 1,62 (m, 2H, CH2), 2.55 (t, 2H, CH2), 3.18 (s, 2H, 4-CH2), 3.74 (s, 6H, OCH3), 5.02 
(s, 2H, CH2), 6.40 (s, 1H, ArH), 6.76 (s, 1H, ArH), 7.19 (m, 5H, ArH), 13C NMR CDCl3: δ 
14.3 (C), 23.1 (C), 25.6 (C), 29.7 (C), 33.5 (C), 37.7 (C), 56.3 (2C), 87.1 (C), 116.3 (C), 
117.5 (C), 118.6 (C), 122.2 (C), 126.1 (2C), 126.2 (2C), 126.4 (C), 128.5 (2C), 134.3 (C), 
148.2 (C), 148.7 (C), 149.0 (C), 150.1 (C), 164.6 (C). Anal. Calcd. For C26H29BrClN3O3 C, 
57.10; H, 5.34; N, 7.68; Found: C, 57.12, H, 5.32, N, 7.63 %. 
Compound (5c): 1H NMR CDCl3: δ 0.94 (t, 3H, CH3), 1.32 (m, 2H, CH2), 1,60 (m, 2H, 
CH2), 2.53 (t, 2H, CH2), 3.42 (dd, 1H, J=8.0, 4-H), 3.49 (dd, 2H, J=8.0, 4-H), 3.79 (s, 6H, 
OCH3), 4.96 (s, 2H, CH2), 5.24 (dd, 1H, J=4.0, 5-H), 6.34 (s, 1H, ArH), 6.70 (s, 1H, ArH). 
13C NMR CDCl3: δ 14.2 (C), 23.0 (C), 25.7 (C), 33.4 (C), 33.7 (C), 40.8 (C), 56.3 (2C), 68.8 
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 (C), 116.4 (C), 117.4 (C), 118.2 (C), 118.6 (C), 122.1 (C), 126.7 (C), 134.5 (C), 148.2 (C), 
148.6 (C), 149.1 (C), 164.7 (C). Anal.Calcd. For C20H22BrClN4O3; C, 49.86; H, 4.60; N, 
11.63; Found: C, 49.89, H, 4.67, N, 11.53 %.  
Compound (5d): 1H NMR CDCl3: δ 0.97 (t, 3H, CH3), 1.34 (m, 2H, CH2), 1.64 (m, 2H, 
CH2), 2.56 (t, 2H, CH2), 3.38 (dd, 1H, J=8.4, 4-H), 3.42 (dd, 2H, J=8.4, 4-H), 3.46 (dd, 1H, 
J=7.6, CH2Cl), 3.69 (dd, 1H, J=7.6, CH2Cl), 3.75 (s, 6H, OCH3), 5.02 (s, 2H, CH2), 5.12 (m, 
1H, 5-H), 6.40 (s, 1H, ArH), 6.78 (s, 1H, ArH). 13C NMR CDCl3: δ 14.1 (C), 22.8 (C), 25.5 
(C), 33.4 (C), 33.7 (C), 37.8 (C), 51.8 (C), 56.2 (2C), 69.8 (C), 116.4 (C), 117.5 (C), 118.6 
(C), 121.9 (C), 126.2 (C), 134.5 (C), 148.1 (C), 148.6 (C), 149.1 (C), 164.7 (C). Anal.Calcd. 
For C20H24BrCl2N3O3; C, 47.55; H, 4.79; N, 8.32; Found: C, 47.53, H, 4.78, N, 8.35 %. 
Compound (5e): 1H NMR CDCl3: δ 0.95 (t, 3H, CH3), 1.33 (m, 2H, CH2), 1.62 (m, 2H, 
CH2), 2.55 (t, 2H, CH2), 3.35 (dd, 1H, J=8.4, 4-H), 3.40 (dd, 2H, J=8.4, 4-H), 3.44 (dd, 1H, 
J=7.2, CH2Br), 3.64 (dd, 1H, J=7.2, CH2Br), 3.73 (s, 6H, OCH3), 5.00 (s, 2H, CH2), 5.04 (m, 
1H, 5-H), 6.38 (s, 1H, ArH), 6.75 (s, 1H, ArH). 13C NMR CDCl3: δ 14.3 (C), 22.8 (C), 25.6 
(C), 33.6 (C), 33.8 (C), 38.8 (C), 41.0 (C), 56.4 (2C), 70.9 (C), 116.4 (C), 117.4 (C), 118.7 (C), 
122.2 (C), 126.3 (C), 134.4 (C), 148.2 (C), 148.8 (C), 149.1 (C), 164.7 (C). Anal.Calcd. For 
C20H24Br2ClN3O3; C, 43.70; H, 4.40; N, 7.64; Found: C, 43.71, H, 4.42, N, 7.62 %. 
Compound (5f): 1H NMR CDCl3: δ 0.97 (t, 3H, CH3), 1.34 (m, 2H, CH2), 1,63 (m, 2H, 
CH2), 2.32 (dd, 1H, OH), 2.57 (t, 2H, CH2), 3.28 (dd, 1H, J=8.0, 4-H), 3.34 (dd, 1H, J=8.0, 
4-H), 3.52-3.79 (m, 2H, CH2), 3.74 (s, 6H, OCH3), 4.98 (s, 2H, CH2), 5.04 (m, 1H, 5-H), 
6.41(s, 1H, ArH), 6.77 (s, 1H, ArH). 13C NMR CDCl3: δ 14.2 (C), 23.0 (C), 25.7 (C), 33.5 
(C), 33.8 (C), 36.8 (C), 56.3 (2C), 70.6 (C), 77.5 (C), 116.3 (C), 117.4 (C), 118.4 (C), 121.9 
(C), 126.2 (C), 134.5 (C), 148.1 (C), 148.7 (C), 149.0 (C), 164.7 (C). Anal.Calcd. For 
C20H25BrClN3O4; C, 49.35; H, 5.18; N, 8.63; Found: C, 49.33, H, 5.19, N, 8.64 %. 
Compound (5g): 1H NMR CDCl3: δ 0.94 (t, 3H, CH3), 1.35 (m, 2H, CH2), 1,64 (m, 2H, 
CH2), 2.04 (s, 3H, CH3), 2.57 (t, 2H, CH2), 3.30 (dd, 1H, J=8.2, 4-H), 3.37 (dd, 1H, J=8.2, 
4-H), 3.78 (s, 6H, OCH3), 5.02 (s, 2H, CH2), 5.68 (dd, 1H, J=3.8, 5-H), 6.39 (s, 1H, ArH), 
6.77 (s, 1H, ArH). 13C NMR CDCl3: δ 14.3 (C), 21.1 (C), 23.0 (C), 25.6 (C), 33.4 (C), 33.8 
(C), 56.3 (2C), 69.5 (C), 96.3 (C), 116.3 (C), 117.5 (C), 118.6 (C), 121.9 (C), 1.26.2 (C), 
134.4 (C), 148.0 (C), 148.6 (C), 149.1 (C), 164.6 (C), 170.4 (C). Anal.Calcd. For 
C21H25BrClN3O5; C, 48.99; H, 4.89; N, 8.16; Found: C, 48.99, H, 4.88, N, 8.17 %.  
Compound (5h): 1H NMR CDCl3: δ 0.95 (t, 3H, CH3), 1.13 (t, 3H, CH3), 1.33 (m, 2H, CH2), 
1,64 (m, 2H, CH2), 2.28 (q, 2H, CH2), 2.54 (t, 2H, CH2), 3.31 (dd, 1H, J=8.0, 4-H), 3.38 (dd, 
1H, J=8.0, 4-H), 3.75 (s, 6H, OCH3), 4.99 (s, 2H, CH2), 5.66 (dd, 1H, J=4.0, 5-H), 6.35 (s, 1H, 
ArH), 6.74 (s, 1H, ArH). 13C NMR CDCl3: δ 9.5 (C), 14.1 (C), 22.8 (C), 25.6 (C), 30.1 (C), 
33.4 (C), 33.7 (C), 56.3 (2C), 69.4 (C), 96.5 (C), 116.4 (C), 117.4 (C), 118.4 (C), 122.0 (C), 
126.3 (C), 134.3 (C), 148.0 (C), 148.7 (C), 149.1 (C), 164.5 (C), 173.4 (C). Anal.Calcd. For 
C22H27BrClN3O5; C, 49.97; H, 5.15; N, 7.95; Found: C, 49.99, H, 5.13, N, 7.93 %. 
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